REIMAGINING WOMEN’S HEALTH
At Metrodora we have created an integrated medical ecosystem with the vision of advancing women’s health. Our philosophy is science-driven and health-creative. We have developed an entirely new patient centered care model partnered with innovative research initiatives for those with neuroimmune disorders. Disrupting the inequities of the status quo is how we revolutionize medical science and women's health.
ADVANCING WOMEN'S HEALTH
Women's health is so much more than reproductive health. Far less is known about women's health because its study has never been prioritized. Metrodora is changing this through the creation of a world-class medical institute that will treat women with the dignity they deserve and drive research to solve the mystery of why neuroimmune disorders disproportionately impact women.
It is estimated that millions of people in the U.S. suffer from a multisystem disorder that simultaneously affects the nervous, immune, and gastrointestinal systems. At Metrodora we recognize these as neuroimmune disorders. These disorders disproportionately affect women and dramatically impact their quality of life.
Women with neuroimmune disorders are commonly dismissed by the medical system and told their symptoms are due to anxiety, depression, or stress. This results in women experiencing significant diagnostic delays compared to men.
Research on disorders that predominantly affect women remains significantly underfunded, which has had enormous and long-lasting implications for women’s health and society at large.
Metrodora is the blueprint for reimagining women’s health and we will not stop until these disorders are cured. Metrodora’s research initiatives are already underway and when the Metrodora clinic opens in June 2022 to patients we will be a national center of excellence for the care and cure of neuroimmune disorders.
The Metrodora Institute will integrate neurology, immunology, and gastroenterology with genetics, pain management, comprehensive rehabilitation programs, nutritional and neurocognitive therapies, and telehealth services to provide world-class patient-centered care within our 50,000 sq. foot state-of-the-art facility in Salt Lake City, Utah.
A NAME WITH A PURPOSE
Metrodora is named after the first female physician to author a medical text (4th century AD), "On the Diseases and Cures of Women", which at the time significantly advanced women’s health. We seek to continue this tradition.
Our founding team is composed of world-renowned physicians, scientists, and technology leaders, positioning Metrodora as a world leader in the space of neuroimmune disorders and women’s health equity.
Laura A. Pace MD, PhD,
Co-Founder and CEO of Metrodora
Dr. Laura A. Pace is a Co-Founder and Chief Executive Officer of Metrodora. Laura is board certified from the American Board of Internal Medicine in both Internal Medicine and Gastroenterology, and from the United Council of Neurologic Subspecialties in Autonomic Disorders. She has been a leader in the rare disease space for many years and for the past several years has served as the Co-Lead for the adult program for the University of Utah NIH Undiagnosed Diseases Network (NIH UDN) clinical site, Medical Board member for Dysautonomia International and Chair of the Gastrointestinal Working Group for the International Consortium on Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorders. Laura has a BS in Chemistry from Stony Brook University, a MD from the University of Illinois Chicago, and a PHD in Neuroscience from the University of Illinois at Urbana-Champaign. She has advanced research training in the areas of neuroscience, microbial physiology, evolution and genetics, as well as analytical chemistry, studying host-microbe interactions. Additionally, she has advanced clinical training in the physiology, diagnostics, and clinical management of neurogastrointestinal disorders and medical genetics. She has published over 80 peer reviewed journal articles and has received research funding from the National Institutes of Health (NIH) and private foundations.
James Hemp PhD
Co-Founder and CSO of Metrodora
Dr. James Hemp will serve as Chief Scientific Officer for Metrodora. James is an interdisciplinary scientist with over 20 years of research experience spanning biology, chemistry, physics, genetics, and medicine. He has published over 40 peer reviewed journal articles and has received research funding from the National Institutes of Health (NIH), National Science Foundation (NSF), and several private foundations. James received a BS in Honors Physics from the University of Minnesota and a PhD in Biophysics and Computational Biology from the University of Illinois at Urbana-Champaign. He was a prestigious Agouron Postdoctoral Fellow while at Caltech.
Fidji Simo, Metrodora
Co-Founder & President of the Metrodora Foundation
Fidji Simo is a Co-Founder of Metrodora and President of the Metrodora Foundation. She is Chief Executive Officer of Instacart and was previously the Head of Facebook App. She brings a wealth of expertise across business, technology, and advances in artificial intelligence that will position Metrodora as the most innovative research institute on such diseases. Fidji has been recognized by Fortune as part of their “40 under 40” annual ranking of most influential young people in business. She was also #2 on Fast Company’s 2017 list of Most Creative People in Business. Fidji was diagnosed with dysautonomia in 2020 and is committed to using her skills and large platform to cure these diseases.
REIMAGINING WOMEN’S HEALTH
The Metrodora Institute is revolutionizing the diagnosis, treatment, and care of patients with neuroimmune disorders by seamlessly integrating care across multiple specialties. The Institute will consist of a multidisciplinary clinic where coordinated care for patients through all phases of their health journey will be our fundamental focus. Reimagining women’s health care is at the root of everything we do.
Metrodora Foundation will be a global leader in the fight for women's health equity. The Foundation will support this mission through research and advocacy.
It will also serve as a platform to bring knowledge of neuroimmune disorders and the broader topic of women's health to a significantly increased level of public awareness.
In addition to the Metrodora co-founders, President Fidji Simo is joined by Dr. Anthony Philippakis, Chief Data Officer of the Broad Institute and Carol Suh, Partner at Arch Ventures, on the board of the foundation to lead this mission forward.
Metrodora is massively accelerating cures for neuroimmune disorders through the formation of the largest, richest biobank of patient samples and information that is allowing us to forge partnerships with leading scientists, biotechnology and pharma companies. By bringing together the latest advances in technology - such as artificial intelligence - with the best scientific minds, we will create groundbreaking research initiatives that result in breakthrough treatments.
Metrodora’s advocacy initiative will directly and urgently address the systemic failures of our healthcare system through educational outreach to the public, patients, scientific and medical communities, and policy makers about medical conditions that disproportionately affect women. We are committed to thinking outside of the proverbial box to foster a movement with great momentum around women’s health equity.
JOIN US IN OUR
Metrodora is advancing women’s health by providing much needed treatment and advocacy for the patients we serve and accelerating research towards a cure.
Your generosity will assist Metrodora in reimaging women’s health and will go directly towards advancing research and advocacy on neuroimmune conditions. We care deeply about the stewardship of your donation and are grateful for your support.